African-specific alleles modify risk for asthma at the 17q12-q21 locus in African Americans
- PMID: 36175932
- PMCID: PMC9520885
- DOI: 10.1186/s13073-022-01114-x
African-specific alleles modify risk for asthma at the 17q12-q21 locus in African Americans
Abstract
Background: Asthma is the most common chronic disease in children, occurring at higher frequencies and with more severe disease in children with African ancestry.
Methods: We tested for association with haplotypes at the most replicated and significant childhood-onset asthma locus at 17q12-q21 and asthma in European American and African American children. Following this, we used whole-genome sequencing data from 1060 African American and 100 European American individuals to identify novel variants on a high-risk African American-specific haplotype. We characterized these variants in silico using gene expression and ATAC-seq data from airway epithelial cells, functional annotations from ENCODE, and promoter capture (pc)Hi-C maps in airway epithelial cells. Candidate causal variants were then assessed for correlation with asthma-associated phenotypes in African American children and adults.
Results: Our studies revealed nine novel African-specific common variants, enriched on a high-risk asthma haplotype, which regulated the expression of GSDMA in airway epithelial cells and were associated with features of severe asthma. Using ENCODE annotations, ATAC-seq, and pcHi-C, we narrowed the associations to two candidate causal variants that are associated with features of T2 low severe asthma.
Conclusions: Previously unknown genetic variation at the 17q12-21 childhood-onset asthma locus contributes to asthma severity in individuals with African ancestries. We suggest that many other population-specific variants that have not been discovered in GWAS contribute to the genetic risk for asthma and other common diseases.
Keywords: Asthma; Fine mapping; Health disparities; Integrated omics; Whole-genome sequencing.
© 2022. The Author(s).
Conflict of interest statement
K.C.B. is employed by Tempus Labs. G.K.K.H. reports grants from Adare during the conduct of the study. C.M.K. received royalties from editing chapter on treatment of acute asthma. E.M.Z. has served on the DSMB for another researcher’s grant investigating asthma at Wayne State University. L.B.B. reports personal fees from GlaxoSmithKline Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi/Regeneron, Vectura, Circassia, Elsevier, Kinaset, and Vertex outside the submitted work. G.T.O. has received consulting fees from AstraZeneca related to the development of new medications for asthma and COPD and a grant from Janssen. Pharmaceutical related to pathogenetic mechanisms of COPD. R.A.W. has received grants from Aimmune, Astellas, DBV, Genentech, Novartis, Regeneron, and Sanofi. M.C.A. has received consulting fees from Regeneron outside the submitted work. D.J.J. reports grants and personal fees from GlaxoSmithKline and personal fees from Novartis, Pfizer, Sanofi, Regeneron, AstraZeneca, and Vifor Pharma, outside the submitted work. J.E.G. is a paid consultant for AstraZeneca, Meissa Vaccines Inc. and Gossamer Bio, and has stock options in Meissa Vaccines Inc. The remaining authors declare that they have no competing interests.
Figures





References
Publication types
MeSH terms
Substances
Grants and funding
- UL1 RR025780/GF/NIH HHS/United States
- U19 Al095230/GF/NIH HHS/United States
- R01 HL104608/GF/NIH HHS/United States
- F31 HL143891/GF/NIH HHS/United States
- UL1 TR000075/TR/NCATS NIH HHS/United States
- UH3 OD023282/OD/NIH HHS/United States
- UL1 TR001430/GF/NIH HHS/United States
- UM2 Al117870/GF/NIH HHS/United States
- UL1 TR000154/GF/NIH HHS/United States
- R01 HL132523/HL/NHLBI NIH HHS/United States
- GT10892/HHMI/Howard Hughes Medical Institute/United States
- UL1 TR000040/TR/NCATS NIH HHS/United States
- HHSN272201000052I/AI/NIAID NIH HHS/United States
- UL1 TR001430/TR/NCATS NIH HHS/United States
- HHSN272201000052l/GF/NIH HHS/United States
- UL1 TR000075/GF/NIH HHS/United States
- UL1 TR001079/GF/NIH HHS/United States
- UL1 TR000451/GF/NIH HHS/United States
- UM1 Al60040/GF/NIH HHS/United States
- UM2 AI117870/AI/NIAID NIH HHS/United States
- UL1 TR000150/GF/NIH HHS/United States
- UL1 TR001105/GF/NIH HHS/United States
- UL1 TR001422/TR/NCATS NIH HHS/United States
- UM1 Al114271/GF/NIH HHS/United States
- U19 AI162310/AI/NIAID NIH HHS/United States
- UM1 Al160040/GF/NIH HHS/United States
- R01 HL104608/HL/NHLBI NIH HHS/United States
- UG3 OD023282/OD/NIH HHS/United States
- P01 AI148104/AI/NIAID NIH HHS/United States
- TL1 TR002388/GF/NIH HHS/United States
- UL1 TR000040/GF/NIH HHS/United States
- U19 AI095227/AI/NIAID NIH HHS/United States
- HHSN272200900052C/AI/NIAID NIH HHS/United States
- UL1 TR000077/GF/NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical